Opinions Split On Newly Approved Myeloma Therapies At ASH
This article was originally published in Scrip
Executive Summary
Doctors debated which new therapies they would prefer to use for the treatment of multiple myeloma and when they thought emerging treatments should become an option for their patients, during the first day of the Annual Meeting for the American Society of Hematology (ASH).